ArticleHeliyon2024
Cross-neutralization of Influenza A by SARS-CoV-2 specific neutralizing antibodies and polyclonal plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A?
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Paper-Based Biosensors for Monitoring Binding, Blocking, and Surrogate Neutralizing Antibody Responses Against Viral Infections.Biosensors · 2026Review
- The interplay of influenza and COVID-19 in Germany, January 2020 - December 2022: a study of competitive disease dynamics with quarantine measures and partial cross-immunity.BMC public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to sparse information from various countries, the seasonal influenza virus circulation has drastically decreased during the COVID-19 pandemic. Here, we show the cross-reactivity of anti-SARS-CoV-2 antibodies against influenza viruses. Plasma samples were collected from 311 SARS-CoV-2 infected individuals. The samples were tested for antibody titers against SARS-CoV-2 by ELISA and seasonal influenza virus strains (influenza A/H1N1, A/H3N2, B/Yamagata, and B/Victoria) using a Hemagglutination Inhibition Assay (HAI). In addition, SARS-CoV-2 antibody-positive but Influenza antibody-negative samples (n = 16) were investigated to determine the SARS-CoV-2 antibody-neutralizing potential against influenza viruses by microneutralization (MN) assay. The SARS-CoV-2 genomes were sequenced using Illumina next-generation sequencing, and an in-silico protein structural analysis was performed to identify epitope and antibody binding similarities between SARS-CoV-2 and influenza viruses. Among 16 samples that didn't contain antibodies against Influenza A strains (H1N1 and H3N2), five showed high (MN titer≥20), and six showed moderate (MN titer≥10) capability to neutralize Influenza A. Subsequent in-silico analysis revealed that most efficient binding (>8 kcal/mol) was found between the antibodies of SARS-CoV-2 delta variant (ΔG) with influenza A/H1N1 HA (Hemagglutinin), A/H3N2 HA, A/H1N1 NA (Neuraminidase), and A/H3N2 NA glycoproteins with -12.4, -9.3, -10.1, and -11.7 kcal/mol, respectively. This investigation revealed that neutralizing antibodies of the delta variant cross-reacted with the Influenza A virus, which might protect against influenza viruses and reduce and shift the seasonal influenza circulation during the COVID-19 pandemic. Our findings warrant further study to explain the probable mechanisms of this cross-reactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.